Viatris

VTRS62

S&P500

$13.370.00%$0.00

S&P500

VTRS62

$13.37

0.00%$0.00

S&P500

Performance History

Key Stats
Open	$13.37
Prev. Close	$13.37
EPS	-0.73

Next Earnings Date	Dec 13, 2024


PE Ratio	-

	LOW	HIGH
Day Range	13.37	13.37
52 Week Range	8.74	13.62

Ratios







EPS	-0.73

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Viatris (VTRS)

Viatris Inc (VTRS) is a pharmaceutical company that specializes in the development, manufacturing, and distribution of generic and biosimilar medicines. The company was formed through a merger between Mylan N.V. and Upjohn Inc., a division of Pfizer Inc., in November 2020. Viatris aims to improve access to high-quality, affordable medicines for patients worldwide.

The stock price history of Viatris Inc (VTRS) reflects the company's performance in the market. Investors can track the fluctuations in the stock price over time to make informed investment decisions. It is important to note that past performance is not indicative of future results.

Websitecall_made

Sector: Healthcare
Industry: Drug Manufacturers—Specialty & Generic
CEO: Mr. Scott Andrew Smith
Headquarters: Canonsburg
Employees: 38000
Exchange: NASDAQ

Keep an eye on Viatris

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Viatris 's (VTRS) price per share?

The current price per share for Viatris (VTRS) is $13.37. The stock has seen a price change of $0 recently, indicating a 0% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Viatris (VTRS)?

For Viatris (VTRS), the 52-week high is $13.62, which is 1.87% from the current price. The 52-week low is $8.74, the current price is 52.97% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Viatris (VTRS) a growth stock?

Viatris (VTRS) has shown an average price growth of -3.66% over the past three years. It has received a score of 53 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Viatris as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Viatris (VTRS) stock price performance year to date (YTD)?

As of the latest data, Viatris (VTRS) has a year-to-date price change of 17.38%. Over the past month, the stock has experienced a price change of 16.46%. Over the last three months, the change has been 13.79%. Over the past six months, the figure is 28.43%.

help

Is Viatris (VTRS) a profitable company?

Viatris (VTRS) has a net income of $54.7M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 41.74% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 13.88% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $15.43B, although specific revenue growth data is currently not available. The gross profit is $6.44B. Operating income is noted at $766.2M. Furthermore, the EBITDA is $2.89B.

help

What is the market capitalization of Viatris (VTRS)?

Viatris (VTRS) has a market capitalization of $15.96B. The average daily trading volume is 0, indicating the stock's liquidity and investor engagement.

News

ZOLLINGER-ELLISON SYNDROME

Zollinger-Ellison Syndrome (Gastrinoma) Global Clinical Trials Review 2024: Country (G7 & E7), Phase, Trial Status, End Points Status and Sponsor Type

OPHTHALMIC DISEASE

THERAPEUTICS

AGE-RELATED MACULAR DEGENERATION

DIABETIC MACULAR EDEMA

RETINAL DISORDERS

Oct 15, 2024

Ophthalmic Disease Therapeutics Market Analysis by Age-related Macular Degeneration, Diabetic Macular Edema, & Other Retinal Disorders - Global Forecast to 2030

IRRITABLE BOWEL SYNDROME

SURGICAL PROCEDURES

Oct 10, 2024

Global Antiemetics Drugs Market to Exhibit Growth at a CAGR of ~6% by 2030 | DelveInsight

ANTI-RETROVIRAL DRUGS

HIV